Smith Square Partners acts as financial adviser to LiDCO Group Plc in relation to a recommended cash offer by Masimo LHC Limited

Smith Square Partners is pleased to report the announcement in relation to its client LiDCO Group Plc (AIM:LID, “LiDCO”) of a Recommended Cash Offer from Masimo Corporation (NASDAQ: MASI, “Masimo”). Smith Square Partners is acting as Rule 3 adviser to LiDCO. 

The Offer price of 12 pence per LiDCO Share values the total issued share capital of LiDCO at approximately £31.1 million on a fully diluted basis. This equates to an enterprise value of approximately £27.6 million or 2.7 times LiDCO’s revenue for the twelve months ended 31 July 2020 and approximately 3.7 times LiDCO’s revenue for the last full financial year ended 31 January 2020.

Masimo is a private company established by Masimo Corporation as an indirect, wholly owned subsidiary specifically for the purpose of making the Offer. Masimo Corporation is a global medical technology company that develops, manufactures, distributes, and licenses innovative patient monitoring technologies, medical devices, and a wide array of sensors. Over the past three decades, Masimo Corporation has established a track record and reputation for developing innovative technologies that improve patient outcomes and today it has a market capitalisation of approximately $12 billion.

LiDCO develops, manufactures and sells advanced hemodynamic monitoring devices primarily for critical care and high risk surgical patients. LiDCO’s primary markets are the United Kingdom, the US and certain markets in continental Europe, China and Japan. LiDCO’s equipment measures crucial physiological parameters such as cardiac output, stroke volume and systematic vascular resistance, monitoring the amount of blood flowing around the body, the requirement for intravenous fluids, and vasoactive support to help ensure that the body’s tissues and organs are adequately oxygenated. Revenue is principally generated through the sale of single-use disposables, and/or recurring usage licences into a growing installed base of LiDCO-enabled monitors. In addition, LiDCO distributes a number of complementary third-party products.

The transaction will enable LiDCO’s technologies to compete with those of much larger global peers and to gain further market share in the US and other international markets. Moreover, the integration of LiDCO’s continuous cardiac output (“CCO”) technology  into Masimo’s portfolio will provide hospitals with integrated monitoring solutions in a single device and allow greater market penetration through Masimo’s distribution channels. The transaction will also offer shareholders the opportunity to realise the value of their holdings at a significant premium to recent trading prices, as well as in a shorter timeframe than would perhaps have been achieved under LiDCO’s existing growth strategy as an independent company.

Commenting on the Offer Peter Grant, Non-Executive Chairman said: “The LiDCO Board shares Masimo’s belief that, by adding effective CCO solutions to its product mix, the customer value proposition will be enhanced and LiDCO’s products can achieve greater market penetration through the Masimo Group’s distribution channels. The LiDCO Board therefore believes that the prospects for and speed of adoption of LiDCO’s technology, particularly in the important US market, will be materially enhanced by LiDCO becoming part of the Masimo Group.”

Filter by:

Sector:

Type: